Iqvia (IQV) Stock
Global provider of clinical research services and extensive data. Here's the price, business snapshot, and what's worth knowing about Iqvia in September 2026.
IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, real-world data, and analytics to the life sciences industry. It operates as a contract research organisation (CRO) delivering clinical trial management, regulatory support and commercial analytics, combining operational trial capabilities with large proprietary healthcare datasets and technology platforms. The business benefits from structural trends: pharmaceutical and biotech firms outsourcing R&D, rising demand for real-world evidence and use of analytics/AI to shorten time-to-market. With a market capitalisation around $37.2bn, IQVIA’s scale and global footprint are competitive advantages, though growth depends on contract wins, regulatory trends and continued tech investment. Key risks include competitive pressure, project concentration, regulatory and data-privacy challenges, and sensitivity to R&D budgets. This summary is for general educational purposes only and not personal investment advice; values can fall as well as rise and investors should check current filings and suitability for their circumstances.
Why It’s Moving
IQVIA’s earnings beat and expanding data platform are fueling renewed stock momentum.
- IQVIA’s second-quarter results exceeded expectations, with adjusted EPS of $3.15 and revenue of $4.37 billion, indicating that demand for clinical research and healthcare analytics remains resilient.
- Morgan Stanley lifted its valuation view on September 16 while retaining an Equalweight stance, reflecting stronger recent momentum but continued caution about the shares’ elevated valuation.
- IQVIA Digital expanded integrations with The Trade Desk and Veeva Crossix, giving pharmaceutical advertisers more real-time measurement and optimization tools and strengthening the company’s data-platform growth story.
IQVIA’s earnings beat and expanding data platform are fueling renewed stock momentum.
- IQVIA’s second-quarter results exceeded expectations, with adjusted EPS of $3.15 and revenue of $4.37 billion, indicating that demand for clinical research and healthcare analytics remains resilient.
- Morgan Stanley lifted its valuation view on September 16 while retaining an Equalweight stance, reflecting stronger recent momentum but continued caution about the shares’ elevated valuation.
- IQVIA Digital expanded integrations with The Trade Desk and Veeva Crossix, giving pharmaceutical advertisers more real-time measurement and optimization tools and strengthening the company’s data-platform growth story.
Sixth Month Growth Performance
When is the next earnings date for IQVIA HOLDINGS INC (IQV)?
IQVIA Holdings (NYSE: IQV) is currently expected to report its third-quarter 2026 earnings on November 3, 2026. The date remains an estimate rather than a formally confirmed company announcement. This timing is consistent with IQVIA’s historical pattern of reporting quarterly results in late October or early November.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying IQVIA's stock, believing it has potential to reach a higher price.
Financial Health
IQVIA is performing well with strong revenue, cash flow, and profit margins, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Research Demand
Outsourcing of drug development supports recurring project flow and long contract cycles, though revenues can vary with client R&D budgets and competitive pressures.
Global Footprint
A wide international presence helps win multinational trials and diversify revenues, but exposes the company to regulatory and currency headwinds.
Data and Analytics
Proprietary datasets and analytics platforms are differentiators as life sciences firms seek real‑world evidence and AI‑driven insights, though data governance is an ongoing risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
